What is Crinetics Pharmaceuticals's SG&A?

Crinetics Pharmaceuticals (CRNX) reported SG&A of $47.83M in Q4 2025.

How has Crinetics Pharmaceuticals's SG&A changed year-over-year?

Crinetics Pharmaceuticals's SG&A increased by 91.8% year-over-year, from $24.93M to $47.83M.

What is the long-term trend for Crinetics Pharmaceuticals's SG&A?

Over 2 years (2023 to 2025), Crinetics Pharmaceuticals's SG&A has grown at a 81.5% compound annual growth rate (CAGR), from $58.09M to $191.33M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Crinetics Pharmaceuticals CRNX SG&A

SG&A at other companies

Neurocrine BiosciencesNBIX

$318.5M+15.2%

Corcept TherapeuticsCORT

$145.36M+60.3%

Catalyst PharmaceuticalCPRX

$49.32M+5.1%

United TherapeuticsUTHR

$184.1M+8.2%

Amneal Pharmaceuticals, Inc.AMRX

$138.86M+17.4%

Rhythm Pharmaceuticals, Inc.RYTM

$63.59M+62.7%

Segments

By segment

See full

Reportable Segment$50.83M+43.1%

Other financials

Income statement

See full

Revenue$10.7M+2,873%

Gross profit$10.5M+2,818%

Operating income-$140.4M-26.0%

Net income-$127.8M-32.1%

EPS (diluted)-$1.23-18.3%

Balance sheet

See full

Cash & equivalents$115.1M+20.1%

Total debt$47.9M-5.8%

Total equity$1.3B+2.1%

Total assets$1.4B+2.9%

Cash flow

See full

Operating cash flow-$124.7M-41.0%

CapEx$820.0K-33.8%

Free cash flow-$125.5M-40.0%

Valuation

See full

Market cap$3.79B+21.9%

Profitability

See full

Gross margin150%-15.6pp

Operating margin-3,020.3%-1,463pp

Net margin-2,747.2%-1,328pp

FCF margin-2,321.7%-1,122pp

Returns & leverage

See full

Return on equity-39.2%+14.5pp

Debt / equity0×0.0×

Current ratio18.6×-3.9×

Where this comes from

Reported directly by Crinetics Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Crinetics Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Crinetics Pharmaceuticals's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Crinetics Pharmaceuticals's SG&A?: Crinetics Pharmaceuticals (CRNX) reported SG&A of $47.83M in Q4 2025.
How has Crinetics Pharmaceuticals's SG&A changed year-over-year?: Crinetics Pharmaceuticals's SG&A increased by 91.8% year-over-year, from $24.93M to $47.83M.
What is the long-term trend for Crinetics Pharmaceuticals's SG&A?: Over 2 years (2023 to 2025), Crinetics Pharmaceuticals's SG&A has grown at a 81.5% compound annual growth rate (CAGR), from $58.09M to $191.33M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.